Recursion

See you at #SLAS2026! Two of our AI drug discovery experts are presenting at the SLAS International Conference & Exhibition Feb. 7-11 in Boston - on Industrializing Drug Discovery with ML and Leveraging AI to Map Cellular Morphology Across Imaging Modalities. www.slas.org/events-calen...

YouTube video by Google Mapping New Medicines | Where the Internet Lives

A new episode of Google’s podcast #WhereTheInternetLives looks at Recursion's approach to making new medicines – relying on massive proprietary datasets spanning biology, chemistry and patient data; supercomputing; and an end-to-end AI platform. www.youtube.com/watch?v=o-8W... #GoogleDataCenters

Leveraging AI & real-world patient data to accelerate drug discovery. In a recent webinar, Sid Jain and Hayley Donnella of Recursion spoke to Shane Woods at Tempus AI about how patient data is driving the latest advances in AI drug discovery. www.tempus.com/resources/co... #TechBio #data 🧪

YouTube video by Recursion Recursion's Positive Phase 1b/2 Results from the Ongoing TUPELO Study of REC-4881 for FAP

Beth Bruckheimer, PhD, VP of Clinical Development, shared details on our positive Phase 1b/2 results from the ongoing TUPELO study of REC-4881 for Familial Adenomatous Polyposis (FAP), which offers new hope for patients. www.youtube.com/watch?v=mv0c...

🚀 Recursion has been laying the foundation for a virtual cell from day one – including massive-scale, proprietary biological & chemical datasets, AI models & one of the industry’s most powerful supercomputers. Learn about our progress & what's next: www.recursion.com/news/since-i... #virtualcell

YouTube video by Recursion AI in Life Sciences Momentum in London: Recursion at Jefferies and London Life Sciences Week

🚀 The energy & momentum happening around life sciences in London – fueled by innovation and investment in #AI – is undeniable, and it was on full display last week at the Jefferies Global Healthcare Conference & London Life Sciences Week presentations and events. www.youtube.com/shorts/r2iwx...

Mapping Microglia To Unlock New Paths in Neuroscience Dr. Najat Khan of Recursion shared insights into the creation of the Microglia Map and what it could mean for future drug discovery.

In a new story in Technology Networks, incoming CEO and President Najat Khan shared insights into the creation of the Microglia Map in partnership with Roche and Genentech and what it could mean for future drug discovery. #neuroscience #microglia #TechBio www.technologynetworks.com/drug-discove...

YouTube video by Recursion One Thing I Wish My Family Understood About My Work at Recursion

In a new video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts: “What is one thing you wish your families understood about the work that you do?” For many, it’s all about the patients.
#onething #Recursionaut #culture #TechBio #drugdiscovery

www.youtube.com/shorts/ougrI...

Presenting REC-102: Preclinical in vivo updates for a potential ENPP1 inhibitor for the treatment of hypophosphatasia (HPP). Results of the study have been published in the Journal of Bone and Mineral Research.
👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio

At the inaugural TEDx Tribeca on Dec. 3, Recursion incoming CEO and current Chief R&D Officer and Chief Commercial Officer Najat Khan will present her personal journey merging science and technology to make new medicines and improve the lives of patients. www.ted.com/tedx/events/... #NYC #TED #TEDx

Recursion announced a leadership transition plan to drive the next phase of its growth. Effective Jan. 1st, Chris Gibson, Co-Founder and CEO, will transition to Chairman of the Board, Najat Khan, PhD, Chief R&D and Commercial Officer, will be named CEO and President. ir.recursion.com/news-release...

YouTube video by Recursion The Making of the World's First Microglia Map to Explore New Targets for Neurological Diseases

In our latest Explain the Impact video, we share the inside story of the world's first Microglia Map from Recursion and Roche and Genentech to help unlock new targets in neurodegenerative diseases. #neuroscience #techbio youtube.com/shorts/xvPIQ...

How a First-of-its-Kind “Microglia Map” from Recursion and Roche and Genentech Could Unlock New Treatments for Neurodegenerative Diseases A first-of-its-kind whole genome map from researchers at Recursion with partners Roche and Genentech offers a new approach to exploring novel targets and pathways for a wide range of neurological dise...

💥 Recursion has achieved a $30 million milestone payment from its partners, Roche and Genentech, following the acceptance of the Microglia Map – a first-of-its-kind whole genome map of the brain’s immune cells.

👉Learn more: www.recursion.com/news/how-a-f... #neuroscience #TechBio

YouTube video by Recursion TechBio Talks Episode 3: Air Street Capital's Nathan Benaich with Host Chris Gibson

The 3rd episode of TechBio Talks is now live, featuring leading AI investor Nathan Benaich of Air Street Capital with host Chris Gibson discussing the evolving landscape of AI in drug discovery, the biggest trends in Nathan’s new State of AI Report, and more! www.youtube.com/watch?v=MUjT...

YouTube video by Recursion One Thing That Makes Me Excited to Come to Work at Recursion

What gets you excited?

In this video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts to share the “one thing” that most excites them about their work. #OneThing #culture

www.youtube.com/shorts/zQDQq...

Today, cofounder & CEO Chris Gibson spoke on the Main Stage at #GITEX to discuss how the convergence of AI, data, & DNA is fundamentally changing the way we discover medicines. As he wrote: “This is more than just a shift in technology — it’s a re-architecting of the scientific process itself."

🎫 Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will join leading experts from healthcare, technology, and public policy for Google Cloud’s Cancer AI Symposium on Oct. 30 at Google NYC, exploring how #AI is currently transforming #cancer care – and what’s to come. 🧪

Inside the AI transformation of drug discovery.
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio

🎙️ Subscribe to TechBio Talks now on:
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...
▪️ Apple: podcasts.apple.com/us/podcast/t...

Announcing TechBio Talks Episode 2: A deep dive into phenomics, open science and virtual cells.

Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵

TechBio Talks Episode 1: MIT's Regina Barzilay with Host Najat Khan Spotify video

👇 Check out TechBio Talks on:
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...
▪️ Apple: podcasts.apple.com/us/podcast/t...
or wherever you get your podcasts!

YouTube video by Recursion Using Machine Learning to Predict Patient Response to Treatment

In a clip from our podcast TechBio Talks, MIT's Regina Barzilay tells host Najat Khan how we can leverage machine learning to better predict how a patient will respond to treatments, to improve his or her condition for the “longest time with minimal side effects.” www.youtube.com/shorts/uSEM1... 🧵

Careers at Recursion: Join Our Mission | Recursion Embark on a career journey with Recursion. Dive into opportunities, culture, and the impact you can make. Apply to work with us today!

Driving this industry-defining innovation takes bold, bilingual thinkers who collaborate across disciplines, and push back against the status quo.

If this sounds like your kind of mission, we're hiring. www.recursion.com/careers

👉See the list: www.fastcompany.com/best-workpla...

We♥️our innovators.

Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.

At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵

Maintaining our sense of urgency, because patients are waiting.

In a clip from the latest installment in our internal #RXU series – Chief R&D Officer and Chief Commercial Officer Najat Khan talks about the importance of urgency. #TechBio

A recent story in @reuters.com looks at momentum happening in #AI drug discovery, noting that AI adoption across the #pharma industry will lead to “faster and cheaper results” including through reduction in animal testing, a recent push from the #FDA. More: www.reuters.com/business/hea...

“We’re focused on going places that we don’t think other people can.” On 9/8, Chris Gibson & Najat Khan presented at the Morgan Stanley Global Healthcare Conference, addressing macro concerns, platform evolution & what we anticipate from partnership milestones
👉 event.webcasts.com/viewer/event...

A new feature in @financialtimes.com looks at what’s needed for #AI drug discovery to begin delivering on its promises and how the latest #ML breakthroughs paired with over a decade of fit-for-purpose data generation has positioned us for that moment.
👉 www.ft.com/content/9a8a...

🌄 The peak is now the basecamp.

A new feature in @pharmaphorum.bsky.social looks at how Recursion has built the necessary foundation & is now accelerating into a new era of AI-led drug discovery, focused on delivering transformative, first-in-class medicines. pharmaphorum.com/deep-dive/ai...

Read Occam's interview with AIDD leader Najat Khan, PhD. | Occam Global Read Occam's interview with AIDD leader Najat Khan, PhD.

In an interview with Occam, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan outlines the strategy for building a #TechBio company that’s positioned to win.

👉 Read more: www.occam-global.com/blogs/an-int...